Theravance Biopharma Inc. (NASDAQ:TBPH) shares are tumbling on Tuesday following the company’s Phase 3 CYPRESS study did not meet its primary endpoint.
This disappointing news comes as broader markets are experiencing declines, with major indices such as the S&P 500 and Nasdaq both down.
• Theravance Biopharma shares are sliding. What’s pressuring TBPH stock?
Pivotal Trial Failure
The CYPRESS study evaluated ampreloxetine for neurogenic orthostatic hypotension due to multiple system atrophy, but the results fell short, leading the company to wind down the ampreloxetine program.
Neurogenic orthostatic (postural) hypotension is a drop in blood pressure upon standing due to impairment of autonomic function.
Similar trends were observed in the secondary endpoints at week 8.
The company will complete additional analyses of the CYPRESS dataset and phase 3 program, in consultation with external experts, to assess whether the data merits further regulatory discussion.
The assessment is intended to provide additional clarity regarding any remaining value in ampreloxetine for Theravance shareholders.
Theravance Biopharma Reviews Alternatives To Maximize Shareholder Value
Theravance’s board is accelerating its strategic review process to maximize shareholder value.
The company implemented organizational restructuring, impacting about 50% of its workforce, including a complete wind-down of its R&D organization.
The company will incur one-time severance costs of approximately $5 to $7 million and reduce operating expenses by about 60% year over year.
Theravance Biopharma’s Technical Analysis
Currently, the stock is trading 27.34% below its 52-week high of $21.03 and is positioned closer to its 52-week lows than its highs.
The stock’s recent performance reflects significant volatility, with no moving averages available for a more detailed analysis.
The RSI is not available, indicating a neutral stance, and there are no MACD values to assess momentum. Without these indicators, it’s challenging to gauge the stock’s immediate technical outlook.
The countdown is on: Theravance Biopharma is set to report earnings on March 17, 2026.
- EPS Estimate: 34 cents (Up from Loss of 5 cents)
- Revenue Estimate: $41.74 million (Up from $18.75 million)
- Valuation: Forward P/E of 33.2x (Indicates premium valuation)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $20.20. Recent analyst moves include:
- BTIG: Maintains Buy (Target down to $21 on March 3)
- HC Wainwright & Co.: Buy (Raises target to $27 on March 2)
- Oppenheimer: Initiated with Outperform with a target $27 on Dec. 3, 2025)
TBPH Price Action: Theravance Biopharma shares were down 27.05% at $13.82 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Tom Robertson via Shutterstock
